retatrutide trial results 2025 news Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more at our link in bio When the Breakthrough Obesity G-Agonist

24 Epitalon is a 4-amino acid pluripotent peptide and regulator of the brain, pineal glands, and retina

(PubMed) Campone M, Berton-Rigaud D, Joly-Lobbedez F, et al

Always consult a qualified professional regarding health or medical decisions

STEP-3 (N=611, JAMA 2021) combined semaglutide 2.4 mg with intensive behavioral therapy and produced 16.0% mean weight loss at 68 weeks [6]

Colorado's 25% adult obesity rate is the lowest in the nation, and that shapes who walks through a Denver clinic door

( 10.1016/j.molmet.2015.07.008) [DOI] [PMC free article] [PubMed] [Google Scholar] Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, et al